Histocompatibility Antigens Class II
"Histocompatibility Antigens Class II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Large, transmembrane, non-covalently linked glycoproteins (alpha and beta). Both chains can be polymorphic although there is more structural variation in the beta chains. The class II antigens in humans are called HLA-D ANTIGENS and are coded by a gene on chromosome 6. In mice, two genes named IA and IE on chromosome 17 code for the H-2 antigens. The antigens are found on B-lymphocytes, macrophages, epidermal cells, and sperm and are thought to mediate the competence of and cellular cooperation in the immune response. The term IA antigens used to refer only to the proteins encoded by the IA genes in the mouse, but is now used as a generic term for any class II histocompatibility antigen.
| Descriptor ID |
D000949
|
| MeSH Number(s) |
D12.776.395.550.509 D12.776.543.550.440 D23.050.301.500.400 D23.050.705.552.410
|
| Concept/Terms |
Histocompatibility Antigens Class II- Histocompatibility Antigens Class II
- Class II Antigens
- Antigens, Class II
- Class II Histocompatibility Antigens
- Ia-Like Antigens
- Antigens, Ia-Like
- Ia Like Antigens
- IA Antigen
- Antigen, IA
- I-A Antigen
- Antigen, I-A
- Antigens, Immune Response
- Immune Response Antigens
- Immune-Response-Associated Antigens
- Antigens, Immune-Response-Associated
- Immune Response Associated Antigens
- Class II Major Histocompatibility Antigens
- I-A-Antigen
- I A Antigen
- Class II Antigen
- Antigen, Class II
- Ia Antigens
- Antigens, Ia
|
Below are MeSH descriptors whose meaning is more general than "Histocompatibility Antigens Class II".
Below are MeSH descriptors whose meaning is more specific than "Histocompatibility Antigens Class II".
This graph shows the total number of publications written about "Histocompatibility Antigens Class II" by people in this website by year, and whether "Histocompatibility Antigens Class II" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 1 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 1 | 2 |
| 2001 | 1 | 0 | 1 |
| 2002 | 2 | 1 | 3 |
| 2003 | 2 | 2 | 4 |
| 2004 | 0 | 3 | 3 |
| 2005 | 2 | 0 | 2 |
| 2006 | 1 | 2 | 3 |
| 2007 | 2 | 0 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 3 | 4 |
| 2011 | 0 | 2 | 2 |
| 2013 | 1 | 2 | 3 |
| 2014 | 0 | 3 | 3 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2018 | 0 | 2 | 2 |
| 2019 | 1 | 1 | 2 |
| 2020 | 2 | 0 | 2 |
| 2022 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Histocompatibility Antigens Class II" by people in Profiles.
-
PepQueryMHC: rapid and comprehensive tumor antigen prioritization from immunopeptidomics data. Genome Biol. 2025 Dec 23; 26(1):434.
-
Assessment of human leukocyte antigen-based neoantigen presentation to determine pan-cancer response to immunotherapy. Nat Commun. 2024 Feb 08; 15(1):1199.
-
Current perspectives on mass spectrometry-based immunopeptidomics: the computational angle to tumor antigen discovery. J Immunother Cancer. 2023 10; 11(10).
-
A previously unappreciated polymorphism in the beta chain of I-As expressed in autoimmunity-prone SJL mice: Combined impact on antibody, CD4 T cell recognition and MHC class II dimer structural stability. Mol Immunol. 2022 03; 143:17-26.
-
RACK7 recognizes H3.3G34R mutation to suppress expression of MHC class II complex components and their delivery pathway in pediatric glioblastoma. Sci Adv. 2020 07; 6(29):eaba2113.
-
MHC class I and II peptide homology regulates the cellular immune response. FASEB J. 2020 06; 34(6):8082-8101.
-
MHC genotyping from rhesus macaque exome sequences. Immunogenetics. 2019 09; 71(8-9):531-544.
-
Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat Med. 2019 04; 25(4):603-611.
-
Chimeric antigen receptor (CAR) T cells targeting a pathogenic MHC class II:peptide complex modulate the progression of autoimmune diabetes. J Autoimmun. 2019 01; 96:50-58.
-
The parasite-derived rOv-ASP-1 is an effective antigen-sparing CD4+ T cell-dependent adjuvant for the trivalent inactivated influenza vaccine, and functions in the absence of MyD88 pathway. Vaccine. 2018 06 14; 36(25):3650-3665.